PLIANT THERAPEUTICS, INC. (PLRX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PLRX currently has 61.8M outstanding shares. with significant dilution risk as 42.7M authorized shares could dilute existing holders by 69.1%. The company has minimally diluted shareholders by 2.65% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 11, 2026 |
10-Q filing | 61.8M shares outstanding |
62M | 43M |
| Mar 30, 2026 |
S-3 filing: The company is filing an S-3 form to register the offering of debt securities, common stock, and preferred stock, with an aggregate value of up to $300,000,000 and is also offering common stock through an at-the-market offering for up to $50,000,000. |
61M | 43M |
| Nov 06, 2025 |
10-Q filing | 61.4M shares outstanding |
61M | 0 |
| Aug 07, 2025 |
10-Q filing | 61.4M shares outstanding |
61M | 0 |
| May 08, 2025 |
10-Q filing | 61.2M shares outstanding |
61M | 0 |
| Mar 03, 2025 |
10-K filing | 60.5M shares outstanding |
61M | 0 |
| Nov 07, 2024 |
10-Q filing | 60.7M shares outstanding |
61M | 0 |
| Aug 07, 2024 |
10-Q filing | 60.4M shares outstanding |
60M | 0 |
| May 06, 2024 |
10-Q filing | 60.2M shares outstanding |
60M | 0 |
| Feb 27, 2024 |
10-K filing | 58.7M shares outstanding |
59M | 0 |
| Nov 09, 2023 |
10-Q filing | 59.7M shares outstanding |
60M | 0 |
| Aug 09, 2023 |
10-Q filing | 59.2M shares outstanding |
59M | 0 |
| May 09, 2023 |
10-Q filing | 56.1M shares outstanding |
56M | 0 |
| Mar 09, 2023 |
10-K filing | 58.9M shares outstanding |
59M | 0 |
| Nov 08, 2022 |
10-Q filing | 46.8M shares outstanding |
47M | 0 |
| Aug 08, 2022 |
10-Q filing | 48.7M shares outstanding |
49M | 0 |
| May 09, 2022 |
10-Q filing | 36.1M shares outstanding |
36M | 0 |
| Mar 01, 2022 |
10-K filing | 35.8M shares outstanding |
36M | 0 |
| Mar 01, 2022 |
POS AM filing: Pliant Therapeutics, Inc. files a POS AM to offer common stock, preferred stock, and debt securities up to $500,000,000 from time to time and shares of common stock having an aggregate gross sales price of up to $150,000,000 from time to time through Cantor Fitzgerald acting as agent. |
36M | 0 |
| Nov 09, 2021 |
10-Q filing | 35.9M shares outstanding |
36M | 0 |
| Aug 09, 2021 |
10-Q filing | 35.7M shares outstanding |
36M | 0 |
| May 10, 2021 |
10-Q filing | 35.6M shares outstanding |
36M | 0 |
| Mar 16, 2021 |
10-K filing | 35.7M shares outstanding |
36M | 0 |
| Nov 10, 2020 |
10-Q filing | 35.4M shares outstanding |
35M | 0 |
| Aug 11, 2020 |
10-Q filing | 35.4M shares outstanding |
35M | 0 |
| May 11, 2020 |
S-1 filing: This S-1 filing is for an offering of common stock, including an option for underwriters to purchase additional shares, and a concurrent private placement to Novartis, with the intention to use the proceeds for clinical development, preclinical programs, business development, working capital, and general corporate purposes. |
180M | 0 |